Kinetic Characteristics of Neutralizing Antibody Responses Vary among Patients with COVID-19
| Autor: | LI, Ling Hua, TU, Hong Wei, LIANG, Dan, WEN, Chun Yan, LI, An An, LIN, Wei Yin, HU, Ke Qi, HONG, Wen Shan, LI, Yue Ping, SU, Juan, ZHAO, San Tao, LI, Wei, YUAN, Run Yu, ZHOU, Ping Ping, HU, Feng Yu, TANG, Xiao Ping, KE, Chang Wen, KE, Bi Xia, CAI, Wei Ping |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Biomedical and Environmental Sciences |
| ISSN: | 2214-0190 0895-3988 |
| Popis: | Objective The coronavirus disease 2019 (COVID-19) pandemic continues to present a major challenge to public health. Vaccine development requires an understanding of the kinetics of neutralizing antibody (NAb) responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Methods In total, 605 serum samples from 125 COVID-19 patients (from January 1 to March 14, 2020) varying in age, sex, severity of symptoms, and presence of underlying diseases were collected, and antibody titers were measured using a micro-neutralization assay with wild-type SARS-CoV-2. Results NAbs were detectable approximately 10 days post-onset (dpo) of symptoms and peaked at approximately 20 dpo. The NAb levels were slightly higher in young males and severe cases, while no significant difference was observed for the other classifications. In follow-up cases, the NAb titer had increased or stabilized in 18 cases, whereas it had decreased in 26 cases, and in one case NAbs were undetectable at the end of our observation. Although a decreasing trend in NAb titer was observed in many cases, the NAb level was generally still protective. Conclusion We demonstrated that NAb levels vary among all categories of COVID-19 patients. Long-term studies are needed to determine the longevity and protective efficiency of NAbs induced by SARS-CoV-2. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|